acitretin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
retinol derivatives 78 55079-83-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • acitretin
  • acitretinoin
  • etretin
  • neotigason
  • soriatane
  • isoacitretin
  • isoetretin
An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of ETRETINATE with the advantage of a much shorter half-life when compared with etretinate.
  • Molecular weight: 326.44
  • Formula: C21H26O3
  • CLOGP: 6.07
  • LIPINSKI: 1
  • HAC: 3
  • HDO: 1
  • TPSA: 46.53
  • ALOGS: -5.83
  • ROTB: 6
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
35 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.83 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 59 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,KDR,KIT,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MAPKAPK5,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 59
kinase-selectivity-class ACVR2B,AXL,BRAF,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,MAP2K6,MAPK7,PDK4,PRKDC,SIK2,STK33,TEK,TGFBR1,TTK 19
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Oct. 28, 1996 FDA STIEFEL LABS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 1041.51 25.17 531 17521 147223 90463172
Skin haemorrhage 579.06 25.17 201 17851 21179 90589216
Carotid artery thrombosis 577.52 25.17 164 17888 8928 90601467
Neurologic neglect syndrome 577.42 25.17 163 17889 8684 90601711
Adjustment disorder 545.80 25.17 159 17893 9483 90600912
Personality disorder 522.52 25.17 163 17889 12281 90598114
Sensory loss 489.68 25.17 170 17882 17905 90592490
Hemiplegia 476.73 25.17 162 17890 15998 90594397
Affect lability 470.54 25.17 165 17887 17898 90592497
Arterial occlusive disease 468.50 25.17 150 17902 12296 90598099
Gangrene 467.57 25.17 151 17901 12725 90597670
Skin exfoliation 456.53 25.17 237 17815 67676 90542719
Motor dysfunction 452.91 25.17 163 17889 19067 90591328
Sinus congestion 448.42 25.17 178 17874 27246 90583149
Coordination abnormal 439.90 25.17 164 17888 21192 90589203
Respiratory tract congestion 438.05 25.17 175 17877 27235 90583160
Sneezing 433.70 25.17 178 17874 29691 90580704
Sinus disorder 412.49 25.17 179 17873 34268 90576127
Eating disorder 379.52 25.17 159 17893 27914 90582481
Hemiparesis 373.31 25.17 163 17889 31656 90578739
Muscle spasticity 360.14 25.17 164 17888 35158 90575237
Angina pectoris 340.93 25.17 163 17889 38997 90571398
Aphasia 333.04 25.17 165 17887 42647 90567748
Dysarthria 295.57 25.17 165 17887 54317 90556078
Rhinorrhoea 292.56 25.17 195 17857 88121 90522274
Cystitis 284.97 25.17 173 17879 66545 90543850
Cataract 260.22 25.17 168 17884 71924 90538471
Influenza like illness 254.99 25.17 173 17879 80438 90529957
Dysphagia 214.27 25.17 178 17874 112100 90498295
Influenza 206.00 25.17 191 17861 139073 90471322
Cerebrovascular accident 189.62 25.17 173 17879 123360 90487035
Chest discomfort 169.26 25.17 171 17881 138194 90472201
Arthritis 164.34 25.17 184 17868 167131 90443264
Blood pressure increased 144.67 25.17 187 17865 197030 90413365
Palpitations 143.97 25.17 156 17896 136572 90473823
Muscular weakness 105.67 25.17 165 17887 206501 90403894
Tongue ulceration 93.08 25.17 34 18018 4134 90606261
Cough 79.27 25.17 205 17847 368757 90241638
Vulvovaginal erythema 77.59 25.17 19 18033 576 90609819
Vulvovaginal swelling 72.10 25.17 19 18033 777 90609618
Anxiety 71.60 25.17 177 17875 309595 90300800
Nasopharyngitis 68.52 25.17 207 17845 406897 90203498
Infusion related reaction 67.06 25.17 4 18048 416776 90193619
Ileal ulcer 66.61 25.17 19 18033 1047 90609348
Genital ulceration 66.49 25.17 19 18033 1054 90609341
Sinusitis 63.99 25.17 181 17871 342907 90267488
Vulval disorder 62.26 25.17 19 18033 1325 90609070
Swelling 61.84 25.17 6 18046 419052 90191343
Gastrointestinal disorder 59.63 25.17 147 17905 256540 90353855
Skin plaque 58.95 25.17 32 18020 9943 90600452
Cutaneous T-cell lymphoma 54.72 25.17 18 18034 1602 90608793
Oral lichen planus 53.50 25.17 15 18037 776 90609619
Pemphigus 52.98 25.17 3 18049 326861 90283534
Inflammatory bowel disease 52.61 25.17 24 18028 5147 90605248
Dactylitis 52.50 25.17 22 18030 3851 90606544
Infected dermal cyst 50.78 25.17 13 18039 474 90609921
Rhesus antigen positive 49.29 25.17 10 18042 124 90610271
Abdominal discomfort 48.98 25.17 17 18035 477311 90133084
Skin lesion 48.96 25.17 48 18004 37317 90573078
Psoriatic arthropathy 48.05 25.17 126 17926 228209 90382186
Malaise 46.57 25.17 235 17817 585751 90024644
Weight increased 46.24 25.17 13 18039 417914 90192481
Drug ineffective 46.01 25.17 448 17604 1383850 89226545
Rash pustular 45.29 25.17 25 18027 8024 90602371
Lichen planus 45.16 25.17 18 18034 2773 90607622
Drug hypersensitivity 45.07 25.17 18 18034 463591 90146804
Pain of skin 44.88 25.17 32 18020 16050 90594345
Confusional state 44.39 25.17 173 17879 386032 90224363
Dyspnoea 43.33 25.17 68 17984 880887 89729508
Palmoplantar pustulosis 43.16 25.17 12 18040 602 90609793
Vulvovaginal candidiasis 42.53 25.17 19 18033 3881 90606514
Rash 42.52 25.17 58 17994 796042 89814353
Abdominal pain upper 41.45 25.17 8 18044 332666 90277729
Arthropathy 41.25 25.17 11 18041 366231 90244164
Pustular psoriasis 40.79 25.17 32 18020 18524 90591871
Psoriasis area severity index increased 40.38 25.17 9 18043 179 90610216
Squamous cell carcinoma 40.02 25.17 25 18027 10076 90600319
Diffuse alopecia 38.98 25.17 13 18039 1207 90609188
Rheumatoid arthritis 38.90 25.17 159 17893 362455 90247940
Dermatitis exfoliative generalised 38.88 25.17 20 18032 5573 90604822
Face oedema 38.35 25.17 34 18018 23284 90587111
Pneumonia 38.12 25.17 237 17815 637822 89972573
Drug ineffective for unapproved indication 37.94 25.17 56 17996 66588 90543807
Squamous cell carcinoma of the oral cavity 37.78 25.17 10 18042 416 90609979
Actinic keratosis 36.27 25.17 16 18036 3172 90607223
Hypoaesthesia 36.21 25.17 9 18043 314201 90296194
Erythrodermic psoriasis 36.20 25.17 12 18040 1094 90609301
Toxicity to various agents 35.68 25.17 7 18045 287839 90322556
Stomatitis 35.52 25.17 6 18046 274692 90335703
Joint swelling 35.42 25.17 29 18023 503271 90107124
Synovitis 35.11 25.17 11 18041 329741 90280654
Guttate psoriasis 34.54 25.17 10 18042 581 90609814
Erythema 34.27 25.17 112 17940 229134 90381261
Lipids increased 34.01 25.17 12 18040 1320 90609075
Contraindicated product administered 33.51 25.17 11 18041 320128 90290267
Chest pain 33.43 25.17 11 18041 319634 90290761
Discomfort 33.32 25.17 7 18045 274328 90336067
Skin burning sensation 33.06 25.17 29 18023 19582 90590813
Abdominal pain 31.49 25.17 20 18032 395701 90214694
Musculoskeletal stiffness 31.37 25.17 10 18042 296522 90313873
Death 31.27 25.17 27 18025 456524 90153871
Neutropenia 31.18 25.17 4 18048 224900 90385495
Weaning failure 31.05 25.17 9 18043 525 90609870
General physical health deterioration 31.04 25.17 16 18036 355099 90255296
Rebound psoriasis 31.00 25.17 7 18045 148 90610247
Systemic lupus erythematosus 30.61 25.17 17 18035 361879 90248516
Oesophageal stenosis 30.43 25.17 15 18037 3821 90606574
Pyrexia 30.31 25.17 230 17822 660255 89950140
Drug intolerance 30.01 25.17 27 18025 447564 90162831
Mouth ulceration 29.38 25.17 38 18014 39936 90570459
Dizziness 28.43 25.17 46 18006 589238 90021157
Impaired healing 28.39 25.17 6 18046 234193 90376202
Somnolence 28.31 25.17 4 18048 209080 90401315
Drug interaction 28.06 25.17 10 18042 276443 90333952
Type IIb hyperlipidaemia 27.88 25.17 5 18047 30 90610365
Asthma 27.77 25.17 7 18045 242153 90368242
Blood albumin increased 27.70 25.17 10 18042 1175 90609220
Fall 27.50 25.17 177 17875 481633 90128762
Mobility decreased 27.34 25.17 8 18044 250726 90359669
Paraesthesia 27.27 25.17 8 18044 250318 90360077
Type 2 diabetes mellitus 27.26 25.17 4 18048 203240 90407155
Hypertension 26.81 25.17 31 18021 457501 90152894
Anaemia 26.50 25.17 19 18033 352783 90257612
Oesophageal ulcer 26.35 25.17 15 18037 5104 90605291
Hepatic enzyme increased 26.35 25.17 20 18032 360716 90249679
Sleep disorder 26.33 25.17 4 18048 198026 90412369
Blood immunoglobulin M decreased 26.24 25.17 10 18042 1367 90609028
Memory impairment 26.18 25.17 4 18048 197240 90413155
Squamous cell carcinoma of skin 25.95 25.17 17 18035 7432 90602963
Keratoacanthoma 25.77 25.17 8 18044 591 90609804

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 756.57 22.57 309 8744 48295 42563987
Drug ineffective 339.28 22.57 528 8525 629669 41982613
Skin plaque 181.73 22.57 62 8991 5801 42606481
Vein rupture 175.95 22.57 41 9012 938 42611344
Psoriatic arthropathy 148.18 22.57 82 8971 24885 42587397
Treatment failure 146.94 22.57 115 8938 62509 42549773
Cutaneous T-cell lymphoma 119.93 22.57 35 9018 1963 42610319
Skin injury 114.45 22.57 36 9017 2605 42609677
Erythrodermic psoriasis 106.64 22.57 28 9025 1058 42611224
Venous injury 102.61 22.57 22 9031 339 42611943
Therapeutic product effect incomplete 99.07 22.57 97 8956 70842 42541440
Hepatic fibrosis 96.44 22.57 37 9016 4835 42607447
Anti-cyclic citrullinated peptide antibody positive 90.98 22.57 28 9025 1884 42610398
Bone cyst 86.34 22.57 26 9027 1625 42610657
Joint ankylosis 85.94 22.57 26 9027 1651 42610631
Injection site papule 85.63 22.57 19 9034 346 42611936
Injection site haemorrhage 84.90 22.57 44 9009 11692 42600590
Dermatitis exfoliative generalised 76.66 22.57 33 9020 5791 42606491
Hepatic cirrhosis 70.97 22.57 47 9006 19655 42592627
Drug intolerance 67.12 22.57 84 8969 80340 42531942
Osteolysis 66.63 22.57 26 9027 3554 42608728
Hand deformity 65.34 22.57 26 9027 3742 42608540
Psoriasis area severity index increased 65.33 22.57 12 9041 78 42612204
Red blood cell sedimentation rate abnormal 64.89 22.57 26 9027 3810 42608472
Pruritus 64.65 22.57 131 8922 188640 42423642
Pain of skin 63.39 22.57 32 9021 8048 42604234
Bone erosion 61.42 22.57 26 9027 4377 42607905
Empyema 59.37 22.57 25 9028 4155 42608127
Squamous cell carcinoma 59.31 22.57 36 9017 12946 42599336
Keratoacanthoma 59.06 22.57 17 9036 907 42611375
Alanine aminotransferase abnormal 58.52 22.57 26 9027 4918 42607364
Injection site swelling 55.17 22.57 38 9015 16935 42595347
Abdominal abscess 54.62 22.57 25 9028 5068 42607214
Skin erosion 53.81 22.57 21 9032 2870 42609412
Gastrointestinal infection 50.84 22.57 26 9027 6717 42605565
Granuloma annulare 50.68 22.57 11 9042 180 42612102
Hyperkeratosis 47.71 22.57 22 9031 4536 42607746
Squamous cell carcinoma of skin 47.38 22.57 31 9022 12695 42599587
Vascular device infection 47.34 22.57 24 9029 6086 42606196
Hemianopia 45.83 22.57 14 9039 918 42611364
Malignant melanoma stage I 44.69 22.57 9 9044 100 42612182
C-reactive protein abnormal 43.12 22.57 26 9027 9235 42603047
Delusion of parasitosis 42.58 22.57 9 9044 129 42612153
Localised infection 42.54 22.57 35 9018 20338 42591944
Phototherapy 40.94 22.57 7 9046 28 42612254
Hidradenitis 40.92 22.57 15 9038 1726 42610556
Hypertension 40.32 22.57 101 8952 167103 42445179
Candida infection 38.72 22.57 34 9019 21576 42590706
Hypercholesterolaemia 37.64 22.57 27 9026 12822 42599460
Superficial spreading melanoma stage unspecified 37.51 22.57 9 9044 234 42612048
Toxicity to various agents 37.43 22.57 3 9050 229133 42383149
Inappropriate schedule of product administration 36.92 22.57 70 8983 95832 42516450
Acute kidney injury 36.89 22.57 16 9037 367321 42244961
Klebsiella infection 35.95 22.57 25 9028 11307 42600975
Thrombotic thrombocytopenic purpura 35.61 22.57 17 9036 3787 42608495
Pityriasis rubra pilaris 35.56 22.57 9 9044 293 42611989
Muscular weakness 34.71 22.57 63 8990 83435 42528847
Enterococcal infection 34.59 22.57 25 9028 12014 42600268
Staphylococcal sepsis 33.47 22.57 24 9029 11390 42600892
Drug ineffective for unapproved indication 33.44 22.57 45 9008 46118 42566164
Basal cell carcinoma 33.39 22.57 32 9021 22701 42589581
Arthropathy 33.16 22.57 36 9017 29561 42582721
Skin disorder 33.08 22.57 28 9025 16916 42595366
Therapeutic product effect decreased 32.79 22.57 41 9012 39109 42573173
Botryomycosis 32.40 22.57 6 9047 41 42612241
Pain in extremity 32.20 22.57 87 8966 150517 42461765
Myalgia 31.99 22.57 66 8987 96014 42516268
Induration 31.51 22.57 11 9042 1099 42611183
Diabetes mellitus 31.11 22.57 50 9003 60037 42552245
Synovitis 30.95 22.57 26 9027 15541 42596741
Death 30.72 22.57 33 9020 471152 42141130
Emotional distress 30.20 22.57 26 9027 16067 42596215
Musculoskeletal stiffness 29.82 22.57 48 9005 57717 42554565
Neuroendocrine tumour of the lung metastatic 29.63 22.57 7 9046 170 42612112
Staphylococcal bacteraemia 29.48 22.57 22 9031 11099 42601183
Device related sepsis 29.33 22.57 15 9038 3872 42608410
Macule 28.32 22.57 12 9041 2023 42610259
Hypotension 27.84 22.57 10 9043 257621 42354661
Skin exfoliation 27.83 22.57 39 9014 41514 42570768
Cutaneous T-cell lymphoma refractory 27.42 22.57 5 9048 31 42612251
Retinal disorder 27.16 22.57 10 9043 1165 42611117
Therapy non-responder 25.73 22.57 43 9010 53316 42558966
Hepatic steatosis 25.63 22.57 27 9026 21421 42590861
Diffuse idiopathic skeletal hyperostosis 25.40 22.57 5 9048 49 42612233
Transaminases increased 25.26 22.57 33 9020 32852 42579430
Type 2 diabetes mellitus 25.25 22.57 25 9028 18446 42593836
Decreased immune responsiveness 24.63 22.57 11 9042 2104 42610178
Fall 23.84 22.57 10 9043 234510 42377772
Skin lesion 23.62 22.57 29 9024 27145 42585137
Dyslipidaemia 23.56 22.57 18 9035 9400 42602882
Dizziness 23.22 22.57 12 9041 249242 42363040
Drug-induced liver injury 22.82 22.57 34 9019 38239 42574043
Rebound effect 22.75 22.57 16 9037 7363 42604919
Dyspnoea 22.69 22.57 37 9016 442584 42169698

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 1631.10 19.20 745 24923 139248 110424383
Skin haemorrhage 573.39 19.20 216 25452 24611 110539020
Neurologic neglect syndrome 557.58 19.20 166 25502 9132 110554499
Carotid artery thrombosis 551.70 19.20 166 25502 9472 110554159
Adjustment disorder 512.22 19.20 161 25507 10634 110552997
Personality disorder 500.83 19.20 165 25503 12672 110550959
Affect lability 447.96 19.20 167 25501 18470 110545161
Sensory loss 446.30 19.20 173 25495 21284 110542347
Arterial occlusive disease 422.91 19.20 152 25516 15156 110548475
Gangrene 416.92 19.20 153 25515 16188 110547443
Sinus congestion 410.34 19.20 180 25488 30279 110533352
Hemiplegia 405.03 19.20 164 25504 22618 110541013
Sinus disorder 404.29 19.20 182 25486 32546 110531085
Sneezing 401.90 19.20 180 25488 31804 110531827
Motor dysfunction 400.87 19.20 166 25502 24240 110539391
Respiratory tract congestion 398.43 19.20 177 25491 30680 110532951
Skin exfoliation 396.03 19.20 249 25419 87402 110476229
Coordination abnormal 395.56 19.20 166 25502 25062 110538569
Eating disorder 347.75 19.20 161 25507 30697 110532934
Muscle spasticity 339.40 19.20 166 25502 35749 110527882
Hemiparesis 307.90 19.20 166 25502 43737 110519894
Aphasia 277.44 19.20 172 25496 58825 110504806
Cystitis 271.87 19.20 177 25491 65859 110497772
Rhinorrhoea 256.34 19.20 203 25465 102463 110461168
Cataract 251.28 19.20 181 25487 79304 110484327
Angina pectoris 249.18 19.20 164 25504 62131 110501500
Drug ineffective 232.02 19.20 824 24844 1519716 109043915
Influenza like illness 221.07 19.20 175 25493 88237 110475394
Dysarthria 215.70 19.20 169 25499 83952 110479679
Influenza 185.41 19.20 212 25456 168889 110394742
Arthritis 181.88 19.20 209 25459 167377 110396254
Cerebrovascular accident 180.00 19.20 216 25452 181068 110382563
Skin plaque 171.10 19.20 75 25593 12570 110551061
Dysphagia 164.03 19.20 190 25478 153410 110410221
Cutaneous T-cell lymphoma 158.51 19.20 50 25618 3334 110560297
Muscular weakness 145.03 19.20 229 25439 248239 110315392
Vein rupture 132.99 19.20 41 25627 2534 110561097
Chest discomfort 129.90 19.20 180 25488 173668 110389963
Blood pressure increased 129.05 19.20 222 25446 258151 110305480
Erythrodermic psoriasis 112.31 19.20 34 25634 1976 110561655
Palpitations 110.27 19.20 159 25509 159053 110404578
Dermatitis exfoliative generalised 101.45 19.20 50 25618 10922 110552709
Psoriatic arthropathy 100.74 19.20 171 25497 196590 110367041
Squamous cell carcinoma 100.06 19.20 59 25609 18404 110545227
Psoriasis area severity index increased 99.32 19.20 21 25647 274 110563357
Pain of skin 85.59 19.20 55 25613 19974 110543657
Injection site haemorrhage 83.82 19.20 66 25602 32962 110530669
Keratoacanthoma 83.08 19.20 25 25643 1423 110562208
Toxicity to various agents 82.67 19.20 8 25660 480547 110083084
Gastrointestinal disorder 81.49 19.20 176 25492 241776 110321855
Tongue ulceration 79.81 19.20 33 25635 4789 110558842
Venous injury 78.42 19.20 22 25646 976 110562655
Vulvovaginal erythema 77.36 19.20 19 25649 498 110563133
Vulvovaginal swelling 74.14 19.20 19 25649 594 110563037
Joint ankylosis 73.49 19.20 26 25642 2471 110561160
Nasopharyngitis 71.07 19.20 227 25441 394134 110169497
Drug ineffective for unapproved indication 70.13 19.20 102 25566 102736 110460895
Rheumatoid arthritis 69.79 19.20 189 25479 299424 110264207
Squamous cell carcinoma of skin 68.02 19.20 45 25623 17158 110546473
Vulval disorder 66.64 19.20 19 25649 894 110562737
Sinusitis 65.96 19.20 184 25484 296504 110267127
Hidradenitis 64.53 19.20 29 25639 5151 110558480
Bone cyst 64.21 19.20 26 25642 3577 110560054
Injection site papule 64.13 19.20 19 25649 1025 110562606
Infusion related reaction 63.84 19.20 7 25661 381155 110182476
Acute kidney injury 62.39 19.20 35 25633 635395 109928236
Pustular psoriasis 62.22 19.20 39 25629 13566 110550065
Dyspnoea 62.09 19.20 101 25567 1106771 109456860
Skin injury 61.70 19.20 26 25642 3956 110559675
Hypotension 58.83 19.20 24 25644 523825 110039806
Skin lesion 56.94 19.20 65 25603 51566 110512065
Rash 55.95 19.20 65 25603 820899 109742732
Neutropenia 55.44 19.20 10 25658 374610 110189021
Death 54.80 19.20 49 25619 698820 109864811
Decreased appetite 54.74 19.20 21 25647 475825 110087806
Cough 53.90 19.20 231 25437 461410 110102221
Ileal ulcer 53.78 19.20 19 25649 1798 110561833
Osteolysis 53.55 19.20 26 25642 5497 110558134
Dizziness 53.50 19.20 50 25618 698143 109865488
Genital ulceration 52.23 19.20 19 25649 1956 110561675
Dactylitis 51.04 19.20 23 25645 4110 110559521
Pityriasis rubra pilaris 50.82 19.20 12 25656 265 110563366
Empyema 50.36 19.20 25 25643 5545 110558086
Hyperkeratosis 48.69 19.20 29 25639 9210 110554421
Rhesus antigen positive 47.76 19.20 10 25658 124 110563507
Pruritus 47.06 19.20 262 25406 581298 109982333
Inflammatory bowel disease 46.93 19.20 26 25642 7208 110556423
Anxiety 46.86 19.20 181 25487 344897 110218734
Oral lichen planus 44.68 19.20 14 25654 913 110562718
Hepatic fibrosis 44.29 19.20 26 25642 8040 110555591
Somnolence 43.87 19.20 8 25660 297441 110266190
Vulvovaginal candidiasis 42.87 19.20 19 25649 3266 110560365
Abdominal abscess 42.14 19.20 26 25642 8793 110554838
Anaemia 42.09 19.20 39 25629 547047 110016584
Hypersensitivity 41.45 19.20 21 25647 403977 110159654
Alanine aminotransferase abnormal 40.79 19.20 26 25642 9308 110554323
Skin erosion 40.63 19.20 22 25646 5832 110557799
Contraindicated product administered 40.46 19.20 5 25663 248262 110315369
Malignant melanoma stage I 40.23 19.20 9 25659 155 110563476
Diffuse alopecia 39.51 19.20 14 25654 1336 110562295
Therapeutic product effect incomplete 39.49 19.20 128 25540 223677 110339954
Lichen planus 39.03 19.20 18 25650 3392 110560239
Induration 38.36 19.20 16 25652 2373 110561258
Stomatitis 38.31 19.20 8 25660 270234 110293397
Onychalgia 37.93 19.20 13 25655 1124 110562507
Rebound psoriasis 36.82 19.20 9 25659 231 110563400
Pericarditis 36.73 19.20 4 25664 219110 110344521
Hyponatraemia 36.42 19.20 4 25664 217649 110345982
Febrile neutropenia 36.37 19.20 14 25654 316753 110246878
Skin disorder 35.91 19.20 47 25621 42866 110520765
Delusion of parasitosis 35.87 19.20 9 25659 258 110563373
Palmoplantar pustulosis 35.75 19.20 12 25656 974 110562657
Sleep disorder 34.95 19.20 3 25665 198641 110364990
Constipation 34.65 19.20 20 25648 357766 110205865
Phototherapy 34.56 19.20 6 25662 24 110563607
Paraesthesia 33.83 19.20 11 25657 276510 110287121
Intentional product use issue 33.80 19.20 8 25660 247898 110315733
Chest pain 33.74 19.20 23 25645 376352 110187279
Guttate psoriasis 33.72 19.20 10 25658 541 110563090
Drug interaction 33.59 19.20 40 25628 500143 110063488
Abdominal pain 33.42 19.20 42 25626 512947 110050684
Granuloma annulare 33.37 19.20 11 25657 844 110562787
Abdominal pain upper 33.12 19.20 20 25648 349091 110214540
Superficial spreading melanoma stage unspecified 32.93 19.20 9 25659 362 110563269
Hypoaesthesia 32.72 19.20 16 25652 314207 110249424
Seizure 32.50 19.20 6 25662 221179 110342452
Dyslipidaemia 32.34 19.20 28 25640 15937 110547694
Platelet count decreased 32.29 19.20 7 25661 230436 110333195
Malaise 32.24 19.20 266 25402 671553 109892078
Infected dermal cyst 32.08 19.20 12 25656 1336 110562295
Loss of consciousness 31.87 19.20 4 25664 196302 110367329
Erythema 31.80 19.20 143 25525 291304 110272327
Musculoskeletal pain 31.56 19.20 3 25665 183020 110380611
Maternal exposure during pregnancy 31.43 19.20 10 25658 254873 110308758
Pain 31.41 19.20 349 25319 954606 109609025
Gastrointestinal infection 31.32 19.20 26 25642 13979 110549652
Dehydration 31.03 19.20 13 25655 279498 110284133
Weight increased 31.00 19.20 31 25637 419613 110144018
Lipids increased 30.96 19.20 13 25655 1960 110561671
Squamous cell carcinoma of the oral cavity 30.84 19.20 10 25658 728 110562903
Muscle spasms 30.78 19.20 13 25655 278144 110285487
Drug abuse 30.35 19.20 3 25665 177408 110386223
Hemianopia 29.31 19.20 14 25654 2854 110560777
Rash pustular 29.07 19.20 24 25644 12805 110550826
Neuroendocrine tumour of the lung metastatic 28.74 19.20 7 25661 177 110563454
Tremor 28.63 19.20 6 25662 202226 110361405
Inappropriate schedule of product administration 28.59 19.20 108 25560 203529 110360102
Face oedema 28.54 19.20 37 25631 33432 110530199
Skin burning sensation 28.44 19.20 30 25638 21795 110541836
Headache 27.87 19.20 320 25348 882057 109681574
Tachycardia 27.75 19.20 9 25659 226636 110336995
Candida infection 27.59 19.20 44 25624 47965 110515666
General physical health deterioration 27.50 19.20 35 25633 425260 110138371
Cutaneous T-cell lymphoma refractory 27.27 19.20 5 25663 29 110563602
Type IIb hyperlipidaemia 26.98 19.20 5 25663 31 110563600
Localised infection 26.90 19.20 41 25627 43007 110520624
Actinic keratosis 26.89 19.20 18 25650 6995 110556636
Hypokalaemia 26.69 19.20 5 25663 182443 110381188
Thrombotic thrombocytopenic purpura 26.66 19.20 18 25650 7093 110556538
Sticky skin 26.58 19.20 5 25663 34 110563597
Mouth ulceration 26.14 19.20 43 25625 48095 110515536
Dry skin 26.11 19.20 69 25599 107584 110456047
Weaning failure 25.73 19.20 9 25659 827 110562804
Injury 25.63 19.20 5 25663 177260 110386371
Cardiac arrest 25.57 19.20 7 25661 196746 110366885
Skin atrophy 25.54 19.20 17 25651 6547 110557084
Drug hypersensitivity 24.83 19.20 42 25626 454048 110109583
Thrombocytopenia 24.38 19.20 27 25641 348858 110214773
Overdose 24.19 19.20 12 25656 233782 110329849
Gastrooesophageal reflux disease 24.16 19.20 6 25662 179970 110383661
Diffuse idiopathic skeletal hyperostosis 24.03 19.20 5 25663 60 110563571
Vascular device infection 23.87 19.20 24 25644 16488 110547143
Memory impairment 23.80 19.20 8 25660 196936 110366695
Treatment failure 23.77 19.20 127 25541 277107 110286524
Oxygen saturation decreased 23.62 19.20 4 25664 156978 110406653
Syncope 23.16 19.20 9 25659 202527 110361104
Malignant neoplasm progression 23.08 19.20 6 25662 174561 110389070
Staphylococcal sepsis 22.76 19.20 24 25644 17430 110546201
Botryomycosis 22.58 19.20 5 25663 82 110563549
Immunoglobulins decreased 22.38 19.20 11 25657 2388 110561243
Loss of personal independence in daily activities 22.18 19.20 4 25664 150016 110413615
Systemic lupus erythematosus 22.18 19.20 16 25652 254322 110309309
Staphylococcal bacteraemia 21.85 19.20 23 25645 16665 110546966
Klebsiella infection 21.73 19.20 25 25643 19984 110543647
Tanning 21.64 19.20 5 25663 100 110563531
Oesophageal stenosis 21.61 19.20 14 25654 5151 110558480
Swelling 21.56 19.20 30 25638 351011 110212620
Blood albumin increased 21.50 19.20 10 25658 1921 110561710
Enterococcal infection 21.38 19.20 25 25643 20341 110543290
Myalgia 21.24 19.20 105 25563 222276 110341355
Transaminases increased 21.17 19.20 46 25622 63344 110500287
Wheezing 21.05 19.20 17 25651 255213 110308418
Blood immunoglobulin M decreased 20.97 19.20 10 25658 2031 110561600
Macule 20.47 19.20 12 25656 3701 110559930
Nausea 20.46 19.20 401 25267 1235289 109328342
Groin infection 20.03 19.20 8 25660 1062 110562569
Leukopenia 19.89 19.20 5 25663 148786 110414845
Xerosis 19.80 19.20 9 25659 1640 110561991
Neuroendocrine tumour of the lung 19.72 19.20 4 25664 42 110563589
Injection site swelling 19.68 19.20 44 25624 61746 110501885
Gastrointestinal haemorrhage 19.52 19.20 7 25661 165511 110398120
Red blood cell sedimentation rate abnormal 19.21 19.20 26 25642 24483 110539148

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D05BB02 DERMATOLOGICALS
ANTIPSORIATICS
ANTIPSORIATICS FOR SYSTEMIC USE
Retinoids for treatment of psoriasis
FDA CS M0018962 Retinoids
FDA EPC N0000175607 Retinoid
MeSH PA D003879 Dermatologic Agents
MeSH PA D007641 Keratolytic Agents
CHEBI has role CHEBI:50176 keratolytic drugs

Related Drugs by ATC class:

D05BB Retinoids for treatment of psoriasis 1 drug
etretinate

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Severe Recalcitrant Psoriasis indication
Lichen planus off-label use 4776004 DOID:9201
Keratosis follicularis off-label use 48611009 DOID:2734
Lamellar ichthyosis off-label use 205550003
Ichthyosiform erythroderma off-label use 268282005
Primary cutaneous T-cell lymphoma off-label use 400122007
Alcoholism contraindication 7200002
Hypercholesterolemia contraindication 13644009
Depressive disorder contraindication 35489007
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Night blindness contraindication 65194006 DOID:8499
Benign intracranial hypertension contraindication 68267002 DOID:11459
Diabetes mellitus contraindication 73211009 DOID:9351
Premature epiphyseal closure contraindication 89493005
Liver function tests abnormal contraindication 166603001
Hypoalphalipoproteinemia contraindication 190785000
Acute pancreatitis contraindication 197456007 DOID:2913
Hypertrophy of bone contraindication 203514008 DOID:205
Drug-induced hepatitis contraindication 235876009
Pregnancy, function contraindication 289908002
Hypertriglyceridemia contraindication 302870006
Cardiovascular event risk contraindication 395112001
Visual impairment contraindication 397540003
Breastfeeding (mother) contraindication 413712001
Obesity contraindication 414916001 DOID:9970
Psychiatric Disturbance contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.17 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Retinoic acid receptor alpha Nuclear hormone receptor AGONIST WOMBAT-PK CHEMBL
Retinoic acid receptor gamma Nuclear hormone receptor AGONIST CHEMBL CHEMBL
Bile salt export pump Transporter IC50 4.74 CHEMBL
Bile salt export pump Transporter IC50 4.71 CHEMBL

External reference:

IDSource
4021061 VUID
N0000148524 NUI
D02754 KEGG_DRUG
16818 RXNORM
C0050559 UMLSCUI
CHEBI:50173 CHEBI
CHEMBL1131 ChEMBL_ID
DB00459 DRUGBANK_ID
D017255 MESH_DESCRIPTOR_UI
5284513 PUBCHEM_CID
7598 IUPHAR_LIGAND_ID
5530 INN_ID
LCH760E9T7 UNII
11379 MMSL
117161 MMSL
4128 MMSL
d03836 MMSL
69427-46-9 SECONDARY_CAS_RN
4021061 VANDF
004121 NDDF
108914001 SNOMEDCT_US
386938006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0093-1135 CAPSULE 10 mg ORAL ANDA 24 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0093-1136 CAPSULE 25 mg ORAL ANDA 24 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0093-1138 CAPSULE 17.50 mg ORAL ANDA 24 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0115-1750 CAPSULE 10 mg ORAL ANDA 17 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0115-1751 CAPSULE 17.50 mg ORAL ANDA 17 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0115-1752 CAPSULE 22.50 mg ORAL ANDA 17 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0115-1753 CAPSULE 25 mg ORAL ANDA 17 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0378-7020 CAPSULE 10 mg ORAL ANDA 27 sections
Acitretin HUMAN PRESCRIPTION DRUG LABEL 1 0378-7023 CAPSULE 25 mg ORAL ANDA 27 sections
ACITRETIN HUMAN PRESCRIPTION DRUG LABEL 1 42291-086 CAPSULE 10 mg ORAL ANDA 25 sections
ACITRETIN HUMAN PRESCRIPTION DRUG LABEL 1 42291-087 CAPSULE 17.50 mg ORAL ANDA 25 sections
ACITRETIN HUMAN PRESCRIPTION DRUG LABEL 1 42291-088 CAPSULE 25 mg ORAL ANDA 25 sections
ACITRETIN HUMAN PRESCRIPTION DRUG LABEL 1 42794-080 CAPSULE 10 mg ORAL ANDA 25 sections
ACITRETIN HUMAN PRESCRIPTION DRUG LABEL 1 42794-081 CAPSULE 17.50 mg ORAL ANDA 25 sections
ACITRETIN HUMAN PRESCRIPTION DRUG LABEL 1 42794-083 CAPSULE 25 mg ORAL ANDA 25 sections
Acitretin Human Prescription Drug Label 1 46708-741 CAPSULE 10 mg ORAL ANDA 15 sections
Acitretin Human Prescription Drug Label 1 46708-742 CAPSULE 17.50 mg ORAL ANDA 15 sections
Acitretin Human Prescription Drug Label 1 46708-743 CAPSULE 25 mg ORAL ANDA 15 sections
Acitretin Human Prescription Drug Label 1 62332-741 CAPSULE 10 mg ORAL ANDA 15 sections
Acitretin Human Prescription Drug Label 1 62332-742 CAPSULE 17.50 mg ORAL ANDA 15 sections
Acitretin Human Prescription Drug Label 1 62332-743 CAPSULE 25 mg ORAL ANDA 15 sections
ACITRETIN HUMAN PRESCRIPTION DRUG LABEL 1 72162-2222 CAPSULE 10 mg ORAL ANDA 25 sections
ACITRETIN HUMAN PRESCRIPTION DRUG LABEL 1 72162-2223 CAPSULE 25 mg ORAL ANDA 25 sections
ACITRETIN HUMAN PRESCRIPTION DRUG LABEL 1 72162-2224 CAPSULE 17.50 mg ORAL ANDA 25 sections